玛丽巴维尔:作用机制,临床和翻译科学
Kefeng Sun1, Martha Fournier2, Aimee K Sundberg2
1Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.
Clinical and translational science
|December 10, 2023
概括
玛丽巴维尔是一种有效的口服抗病毒药物,用于治疗对其他疗法的耐药性移植后细胞巨乳病毒 (CMV) 感染. 它通过向UL97激酶来抑制CMV复制,为耐火病例提供了新的治疗选择.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
背景情况:
- 移植后的细胞巨乳病毒 (CMV) 感染是一种严重的并发症,通常对标准抗病毒治疗具有耐药性.
- 玛丽巴维尔是一种口服的本齐米达 рибо,开发用于治疗耐药的CMV感染.
- 了解其机制,药理动力学和临床疗效对于移植患者的管理至关重要.
研究的目的:
- 评估马里巴维尔在移植后的CMV感染/疾病治疗中的有效性和安全性.
- 评估马里巴维尔对其他抗病毒药物耐药性CMV菌株的活性.
- 在移植受体中描述马里巴维尔的药理动力学概况.
主要方法:
- 进行了II期剂量范围研究和III期SOLSTICE试验.
- 患有耐火性CMV感染/疾病的患者口服接受了玛丽巴维尔.
- 通过CMV病毒清除来衡量有效性,通过不良事件监测来评估安全性.
主要成果:
- 玛丽巴维尔的口服吸收率很高,并达到治疗度.
- 第二阶段研究显示,不同剂量的CMV病毒清除率相似.
- 第三阶段SOLSTICE试验证实,与研究人员指定的治疗相比,马里巴维尔的CMV病毒性清除优越,以及更低的断药率.
- 常见的不良事件包括腹,恶心,吐和腹.
结论:
- 玛丽巴维尔是一种有效的口服治疗,用于移植后的CMV感染,这些感染对先前的抗病毒疗法不耐药.
- 它的作用机制准UL97激酶,提供针对耐药菌株的活性.
- 马里巴维尔在移植受体中提供了有利的药理动力学特征和可管理的安全性特征.
相关概念视频
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
MicroRNAs
21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
Ribozymes
2.7K
2.7K
Protein-Drug Binding: Mechanism and Kinetics
520
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
520
Immune Response Against Viral Pathogens
789
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
789
Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K


